

## **Environmental Risk Assessment Summary**

### **Faricimab**

#### **Introduction**

The publication of environmental risk assessment summaries is part of Roche's engagement on developing a better understanding of issues regarding pharmaceuticals in the environment (PiE).

New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.

The EMA Guideline on Environmental Risk Assessment (ERA) for Non-GMO Human Medicinal Products [1] requires an ERA for the Marketing Authorisation Application (MAA) of all new medicinal products in the European Union. For proteins and peptides, however, the 'ERA may consist of a justification for not submitting ERA studies, e.g., due to their nature they are unlikely to result in a significant risk to the environment'.

#### **Summary**

Faricimab is a humanized bispecific immunoglobulin G1 (IgG1) monoclonal antibody produced by recombinant DNA technology. It is the active pharmaceutical ingredient used in the product Vabysmo [2].

Vabysmo is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration and with visual impairment due to diabetic macular oedema.

Ecotoxicity and biodegradability tests with Faricimab were not performed. However, acute ecotoxicity tests with green algae, daphnids and fish with other monoclonal antibodies consistently showed no adverse effects at the only tested nominal concentration of 100 mg/L relating to the active substances. Also biodegradability tests with other monoclonal antibodies showed ready biodegradability [3].

Considering human metabolism and the suggested rapid biodegradability and the suggested low acute ecotoxicological properties of Faricimab, no exposure levels of concern to the environment are to be expected. This confirms the general finding that monoclonal antibodies and other protein or peptide active pharmaceutical substances are not expected to pose any risk to the environment [3].

## References

- [1] European Medicines Agency (EMA) (2006/2015): Guideline on the environmental risk assessment of medicinal products for human use. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), 01 June 2006, EMA/CHMP/SWP/447/00 corr 2
- [2] F. Hoffmann-La Roche Ltd (2021): Safety data sheet for Vabysmo, 19 April 2021. <https://www.roche.com/about/sustainability/environment/product-strategy-safety>
- [3] Straub JO (2010): Protein and Peptide Therapeutics: An Example of “Benign by Nature” Active Pharmaceutical Ingredients. *In* Kümmerer K, Hempel M, eds: Green and Sustainable Pharmacy. Springer, Heidelberg, pp 127–133